Previous 10 | Next 10 |
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While overall market breadth remains narrow, the Strategy...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...
Ultragenyx Pharmaceutical (NASDAQ: RARE ) has appointed Mardi C. Dier as EVP and CFO , effective November 2, 2020. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
NOVATO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. D...
NOVATO, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Ernie Meye...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2020 Q2 earnings Read more ...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q2 2020 Earnings Call Jul 30, 2020 , 5:00 p.m. ET Operator Continue reading
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Joshua Higa - Director, Investor Relations and Corporate Communications Emil Kakkis - Chief Executive Officer and President Erik Harris - Chief Commercial Officer ...
Ultragenyx Pharmaceutical (NASDAQ: RARE ) : Q2 GAAP EPS of $0.41 beats by $1.94 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Two U.S. FDA approvals in second quarter 2020 Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million Maintains full year 2020 guidance based on global COVID-19 impact to date NOVATO, Calif., July 30, 2020 (GLOBE NEWSWI...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...